2018 World Premiere: a life-changing therapy for SCI patients


Different key stages of clinical trial with Neurogel

The main objective of the Association is to conduct a clinical trial with NEUROGEL™

The final objective of the Association is to set up clinical trials of NEUROGEL™ specifically for medullar patients with the ultimate goal of obtaining CE marking. This label would signifiy approval has been granted by the French health authorities to make this medical device available to patients. (= A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery) CE

NEUROGEL™ has now been favorably evaluated by the ANSM (the highest health authority in France = FDA) and the agency‘s support for the project testifies to its validity.

The Association’s objective now is to raise enough funds to be able to hire the services of a Research Organization under Contract (CROs), specialized in conducting clinical trials and monitoring follow-ups.

Backed by a CRO, NEUROGEL™ will be able to obtain more substantial funding from sources such as the ANR French National Research Agency), the PHRC (Hospital-based Clinical Research Programs) ou AP-HP (Assistance Publique : Health and Social Welfare – Paris hospitals), the latter agency being the first promoter of clinical trials in France.

We need € 365,000 to procure such partnerships and cover the cost of the required preliminary toxicology tests.

365 000€ is the price to pay to open the doors of a clinical trial. Please support the Association, donate now !

Phases clés